Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 11/20 | 0.43 |
| ▸ | MMP9 | P14780 | 11/20 | 0.43 |
| ▸ | MMP3 | P08254 | 7/20 | 0.40 |
| ▸ | MMP13 | P45452 | 7/20 | 0.40 |
| ▸ | MMP1 | P03956 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7224278 | 0.79 | MMP2 (0.61) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7224498 | 0.73 | MMP2 (0.52) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7232550 | 0.72 | MEN1 (0.47) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7229571 | 0.72 | MMP2 (0.43) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7233446 | 0.68 | MMP2 (0.53) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL17395714 | 0.64 | GAA (0.62) | MEN1KMT2AMAPTGAACYP1A2 | |
| SCHEMBL12239867 | 0.64 | GAA (0.54) | MEN1KMT2AMAPTGAACYP1A2 | |
| SCHEMBL11446014 | 0.63 | SLC6A4 (0.46) | MEN1KMT2AMAPTGAA | |
| SCHEMBL7224858 | 0.63 | MMP2 (0.70) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL15446362 | 0.62 | KMT2A (0.50) | MMP2MMP9MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605604-B1 | Tumour necrosis factor alpha release inhibitors; efficiency treatment of cancers, rheumatic diseases, arthritis, ulcers, atherosclerosis, asthma | LES LABORATOIRES SERVIER (FR) | 2003-08-12 | — | — | US | disclosed |
| EP-1091937-A1 | CARBOXYLIC AND HYDROXAMIC ACID COMPOUNDS INHIBITING METALLOPROTEASES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000000473-A1 | CARBOXYLIC AND HYDROXAMIC ACID COMPOUNDS INHIBITING METALLOPROTEASES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 2000-01-06 | — | — | WO | disclosed |